Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the US
Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...
Biocon Biologics to supply Insulin Aspart drug substance to Civica for US market
Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.
Biocon Biologics, Civica partner to expand Insulin Aspart access in the US
Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration ...
The Pharma Letter2d
Biocon and Civica link up on Insulin Aspart access in USA
Biocon Biologics unit and USA-based Civica Rx, a not-for-profit generic drug and pharmaceutical company, have announced a ...
CNBCTV182d
Biocon Biologics partners with US non-profit co to make diabetes treatment cheaper for Americans
This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...
Rediff Money2d
Biocon Biologics Expands Diabetes Drug Access in US
Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), and Civica, Inc. (Civica), a not-for-profit generic drug and ...
Medical Dialogues2d
Biocon Biologics, Civica join hands to expand Insulin Aspart access in US
Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...
The Financial Express3d
Biocon Biologics partners with Civica to expand Insulin Aspart access in United States
Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...
Biocon arm joins hands with Civica to expand diabetic drug in US
Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.